We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+39.07%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.58B
AUM Growth
+$465M
Cap. Flow
-$336M
Cap. Flow %
-9.38%
Top 10 Hldgs %
52.59%
Holding
77
New
11
Increased
13
Reduced
21
Closed
21

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$61.5M
2
LBRX
LB Pharmaceuticals
LBRX
+$53.2M
3
EXAS
Exact Sciences
EXAS
+$50M
4
AKRO
Akero Therapeutics
AKRO
+$46.4M
5
PCVX icon
Vaxcyte
PCVX
+$28.2M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$176M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$87M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$52.9M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$49.1M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$41.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
51
X4 Pharmaceuticals
XFOR
$381M
$3.84M 0.11%
+1,122,484
New +$2.89M
ACAD icon
52
Acadia Pharmaceuticals
ACAD
$4.5B
$2.24M 0.06%
+105,085
New +$2.49M
AVTX icon
53
Avalo Therapeutics
AVTX
$1.01B
$1.84M 0.05%
144,600
-422,503
-75% -$3.63M
BMRN icon
54
BioMarin Pharmaceuticals
BMRN
$11.9B
$1.35M 0.04%
+24,856
New +$1.42M
ZURA icon
55
Zura Bio
ZURA
$509M
$1.12M 0.03%
259,014
-1,468,548
-85% -$2.64M
CLYM
56
Climb Bio
CLYM
$704M
$1.02M 0.03%
509,789
-530,326
-51% -$985K
ABVX
57
Abivax
ABVX
$10.7B
– –
-3,480,144
Closed -$26.6M
BCYC
58
Bicycle Therapeutics
BCYC
$270M
– –
-1,203,244
Closed -$8.36M
CNTA
59
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-500,000
Closed -$6.57M
DNTH icon
60
Dianthus Therapeutics
DNTH
$5.59B
– –
-2,233,148
Closed -$41.6M
INO icon
61
Inovio Pharmaceuticals
INO
$86.4M
– –
-1,981,370
Closed -$4.03M
INSM icon
62
Insmed
INSM
$22.5B
– –
-1,750,000
Closed -$176M
IVVD icon
63
Invivyd
IVVD
$165M
– –
-8,585,980
Closed -$6.14M
KRRO icon
64
Korro Bio
KRRO
$147M
– –
-277,966
Closed -$3.47M
MRUS
65
DELISTED
Merus
MRUS
– –
-275,000
Closed -$14.5M
NVAX icon
66
Novavax
NVAX
$1.22B
– –
-998,542
Closed -$6.29M
PLRX icon
67
Pliant Therapeutics
PLRX
$66.3M
– –
-3,947,807
Closed -$4.58M
RARE icon
68
Ultragenyx Pharmaceutical
RARE
$2.49B
– –
-1,350,000
Closed -$49.1M
SRPT icon
69
Sarepta Therapeutics
SRPT
$1.65B
– –
-259,800
Closed -$4.44M
SRPT icon
70
PUT
Sarepta Therapeutics
SRPT
$1.65B
– –
-450,000
Closed -$7.7M
SYRE icon
71
Spyre Therapeutics
SYRE
$8.44B
– –
-219,015
Closed -$3.28M
RAPP
72
Rapport Therapeutics
RAPP
$1.99B
– –
-98,237
Closed -$1.12M
TECX
73
Tectonic Therapeutic
TECX
$540M
– –
-1,401,938
Closed -$27.9M
OKUR
74
OnKure Therapeutics
OKUR
$161M
– –
-180,510
Closed -$431K
UPB
75
Upstream Bio Inc
UPB
$341M
– –
-1,442,767
Closed -$15.8M
1 2
3
4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Deep Track Capital held 77 positions worth $3.58B, up 15% from $3.12B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deep Track Capital withdrew a net $336M in Q3 2025, closing 21 positions and reducing 21 holdings. Its most notable exit was Insmed, an estimated $176M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in LB Pharmaceuticals worth $52.9M.

  • Deep Track Capital's largest Q3 2025 buy was LB Pharmaceuticals: 3,352,804 shares worth $52.9M.
  • Deep Track Capital added most to Tarsus Pharmaceuticals in Q3 2025, an estimated $61.5M increase.
  • Deep Track Capital's biggest Q3 2025 reduction was Protagonist Therapeutics, cutting an estimated $87M.
  • Deep Track Capital fully exited Insmed in Q3 2025, selling an estimated $176M.
  • Deep Track Capital's ten largest holdings make up 53% of its $3.58B portfolio in Q3 2025.
  • Deep Track Capital opened 11 new positions and closed 21 in Q3 2025.
  • Deep Track Capital's portfolio value rose 15% quarter-over-quarter to $3.58B.

Based on Deep Track Capital's 13F filing for Q3 2025, filed 14 Nov 2025.